3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
3
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myelomonocytic, Chronic
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Azacitidine
16
Cyclophosphamide
13
fludarabine phosphate
9
Mycophenolic Acid
9
venetoclax
8
Methotrexate
8
Antilymphocyte Serum
8
Tacrolimus
7
Cyclosporine
7
Busulfan
7
Peripheral Blood Stem Cell Transplantation
6
Whole-Body Irradiation
5
Radiotherapy
5
Filgrastim
5
Decitabine
5
Cord Blood Stem Cell Transplantation
5
Rituximab
4
Arsenic Trioxide
4
Sunitinib
3
Sorafenib
3
Methylprednisolone
3
Melphalan
3
Leucovorin
3
Clofarabine
3
ruxolitinib
2
ponatinib
2
idelalisib
2
Sirolimus
2
Moxifloxacin
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Myelomonocytic, Chronic
×
sabatolimab
×
Clear all
NCT04266301
2026-01-13
STIMULUS-MDS2
Novartis
Phase 3
Terminated
530 enrolled
29 charts